key: cord-1013761-dce91tdr
authors: Botwin, G.; Li, D.; Figueiredo, J.; Cheng, S.; Braun, J.; McGovern, D. P. B.; Melmed, G.
title: Adverse Events Following SARS-CoV-2 mRNA Vaccination Among Patients with Inflammatory Bowel Disease
date: 2021-03-31
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2021.03.30.21254607
sha: 1d4b4dd760367bfeec44237bcd11005a66f693a2
doc_id: 1013761
cord_uid: dce91tdr

Patients with immune-mediated inflammatory diseases (IMID) such as inflammatory bowel disease (IBD) on immunosuppressive and biologic therapies were largely excluded from SARS-CoV-2 mRNA vaccine trials. We thus evaluated post-mRNA vaccination adverse events (AE) in 246 vaccinated adults with IBD participating in a longitudinal vaccine registry. In general, AE frequency was similar to that reported in the general population. As in the general population, AE were more common among younger patients, and those with prior COVID-19. We additionally found that AE were less common in individuals receiving biologic therapy. Those with IBD and other IMID on these commonly prescribed therapies can be reassured that the AE risk is likely not increased, and may be reduced, while on biologics.

Patients with immune-mediated inflammatory diseases (IMID) such as inflammatory bowel disease (IBD) receiving immunosuppressive and biologic therapies were underrepresented in SARS-CoV-2 mRNA vaccine trials. 1, 2 Thus, the safety and efficacy of these vaccines in this population is largely unknown. Concerns about adverse events (AE), or reactogenicity, were reported in 70% of those with IBD hesitant to receive SARS-CoV-2 vaccination. 3 We aimed to clarify the AE frequency and severity in this vulnerable vaccine-eligible population.

We enrolled adults with IBD planning to receive, or who already received SARS-CoV-2 vaccination into the Coronavirus Risk Associations and Longitudinal Evaluation-IBD (Corale-IBD) study, a prospective, nationwide registry. We longitudinally surveyed post-vaccination symptoms after each vaccine dose among those who received at least 1 dose of a 2-dose series of either BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccines using a webbased survey administered 8 days following each dose, or at the time of enrollment in the registry if it exceeded 8 days after the last vaccine dose. Symptoms were assessed across multiple organ systems, and were graded by severity (i.e. mild, moderate, or severe impact on activities of daily living, or requiring hospitalization as defined in Baden et al 2 ) and duration (<2 days, between 2 and up to 7 days, or more than 7 days). We analyzed post-vaccination symptoms by age, sex, disease classification, vaccine type, and medication classes using students T-test (R version 3.5.1). Corticosteroids, immunomodulators, biologics, and Janus kinase (JAK) inhibitors were classified as "immune-modifying" therapies. Anti-tumor necrosis factor (TNF)-α, anti-integrin (vedolizumab), anti-interleukin (IL)-12/23, and small-molecule JAK inhibitors were classified as "biologic" therapies. Multivariable regression was used to examine the association of predictors and AE risk while adjusting for potential confounders. The study All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 31, 2021. ; https://doi.org/10.1101/2021.03.30.21254607 doi: medRxiv preprint protocol was approved by the Cedars-Sinai institutional review board. All study participants provided informed consent.

As of March 22, 2021, 246 subjects (mean age 47.4y; 57% female) had completed an AE assessment following at least 1 mRNA vaccine dose (Table) . One hundred forty-one (57%) The overall AE frequency was 39% after dose 1 (D1), and 62% after dose 2 (D2) ( Figure) . Localized injection-site reactions were reported in 38% after D1, and in 56% after D2.

The most common systemic AE included fatigue/malaise (reported by 23% after D1, and 45% after D2), headache/dizziness (14% after D1, 34% after D2) and fever/chills (5% after D1, 29% after D2). Gastrointestinal symptoms were reported by 6% after D1, and 11.5% after D2. These frequencies are similar to the clinical trial reports as well as data from a distinct health-care worker study conducted at the same site and using similar AE capture methods. 1, 4 The vast majority of AE were non-severe. The most common severe symptom after D1 was fatigue/malaise (3%); other severe symptoms were reported by 2% or fewer subjects. The most common severe symptoms after D2 included fatigue/malaise (10%), fever/chills (8%), and headache (8%). Most symptoms resolved in less than 2 days except for injection site reactions, which mostly resolved within 7 days. Twenty-seven severe AE (defined as preventing daily All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 31, 2021. ; https://doi.org/10.1101/2021.03.30.21254607 doi: medRxiv preprint activity) were reported by 16 subjects after D1, and 53 severe AE were reported by 24 subjects after D2. Three subjects were hospitalized after D1: two for fatigue/malaise, and one with gastrointestinal symptoms. Two subjects were hospitalized after D2: one for gastrointestinal symptoms and fever, and one for headache, fever, and fatigue.

AE frequency was higher among subjects younger than 50 years relative to older subjects (47% vs 29% after D1, p=0.011; 73% vs 45% after D2, p=0.003), among those with a prior COVID history (78% vs 37% after D1, p=0.04), and among those with ulcerative colitis relative to those with Crohn's disease (78% vs 55% after D2, p=0.038); no significant differences by disease type were observed after D1. Subjects receiving biologic therapy were less likely to report AE than those not on biologic therapies (36% vs 47% after D1, p=0.17; 54% vs 82% after D2, p=0.013). Similarly, subjects receiving any immune-modifying therapy were less likely to report AE than those not on any immune-modifying therapies (37% vs 48% after D1; p=0.22; 54% vs 86% after D2; p=0.012). No significant differences in any AE frequency were seen based on sex, vaccine type, or history of prior infusion reaction.

We assessed the association of biologic therapies on AE after adjusting for age, disease type, and prior COVID status. Only age was associated with AE after D1 (OR 0.97, 95% CI 0.96-0.99; p=0.015), suggesting reduced AE risk with each year of advancing age. Significant AE associations after D2 included age (OR 0.97, 95% CI 0.94-0.99; p=0.018) and biologic status (OR 0.32, 95% CI 0.10-0.94; p=0.049), suggesting a reduced AE risk among biologic recipients, independent of age. Neither disease type nor prior COVID were retained in the adjusted models, although only 9 patients had previous COVID.

Concerns for AE are an important contributor to persistent vaccine hesitancy, particularly among those with chronic immune-mediated diseases. 3 We found that AE incidence in patients All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. with IBD was generally similar to previously reported rates 1, 2, 4, 5 Furthermore, severe AE or those lasting more than 7 days were very uncommon.

Consistent with the results of post-vaccine responses in general populations, we identified younger age and prior COVID-19 infection as independent predictors of AE to mRNA vaccines among patients with IBD. 1, 2, 4, 5 Notably, individuals on any biologic therapy were less likely to experience AE, particularly after D2. Those with IBD and other IMID on these commonly prescribed therapies can be reassured that the AE risk is likely not increased, and may actually be reduced, while on biologics. It remains to be seen whether biologics are associated with blunted post-vaccination serologic responses, and whether post-vaccine serologic responses correlates with AE frequency or severity. A single mRNA vaccine dose in organ transplant recipients receiving anti-metabolite maintenance immunosuppression therapy were less likely to develop anti-spike serologic responses 2 weeks after vaccination. 6 However, organ transplant recipients have historically had lower vaccine response rates compared to those with IMID. 7 Our study is limited by lack of racial/ethnic diversity, and potential recall bias. However, our results have direct and immediate clinical relevance. Our findings that biologic therapies may attenuate vaccine-related AE can be considered reassuring to patients taking these therapies.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Prefer not to answer 1 (0.6%) 0 (0%) 1 (0.4%) Prefer not to answer 1 (0.6%) 0 (0%) 1 (0.4%)

Hispanic/LatinX 6 (3.6%) 1 (1.2%) 7 (2.8%)

Non-Hispanic/LatinX 147 (89.1%) 75 (92.6%) 222 (90.2%)

Prefer not to answer 0 (0%) 0 (0%) 0 (0%) 

Yes 0 (0%) 0 (0%) 0 (0%) All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 31, 2021. ;

Adverse events after each vaccine dose stratified by biologic use (purple: no biologic; green: any biologic). AEs are graded by severity (darker colors represent more severe AE). AE are also tracked by duration. ("Biologic" refers to use of anti-TNFα, antiintegrin, anti-IL12/23, or JAK-inhibitor) All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 31, 2021. ; https://doi.org/10.1101/2021.03.30.21254607 doi: medRxiv preprint

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

First Month of COVID-19 Vaccine Safety Monitoring -United States

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients